on Adolore Biotherapeutics, Inc.
Adolore BioTherapeutics to Present Gene Therapy Advancements at NANS 2025
Adolore BioTherapeutics, a company focused on innovative treatments for neurological disorders, announced that Dr. Roy C. Levitt will present at the 2025 North American Neuromodulation Society (NANS) annual meeting in Orlando, Florida. Dr. Levitt will showcase the company's CA8* gene therapy aimed at addressing chronic pain and other severe neurological conditions.
The CA8* therapy, developed using replication-defective Herpes Simplex Virus vectors, targets the underlying causes of pain. This approach seeks to offer non-opioid alternatives in response to the current opioid crisis. Adolore is advancing two preclinical programs: one for peripheral neuropathy from erythromelalgia, and the other for knee osteoarthritis-related chronic pain.
Funded by the NIH/NINDS HEAL UH3 Award, Adolore plans to commence first-in-human clinical studies in 2026.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Adolore Biotherapeutics, Inc. news